The effect of PPAR-α agonism on apolipoprotein metabolism in humans
Open Access
- 31 May 2010
- journal article
- review article
- Published by Elsevier BV in Atherosclerosis
- Vol. 210 (1), 35-40
- https://doi.org/10.1016/j.atherosclerosis.2009.11.010
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Potent and Selective PPAR-α Agonist LY518674 Upregulates Both ApoA-I Production and Catabolism in Human Subjects With the Metabolic SyndromeArteriosclerosis, Thrombosis, and Vascular Biology, 2009
- Efficacy and Safety of a Potent and Selective Peroxisome Proliferator Activated Receptor Alpha Agonist in Subjects With Dyslipidemia and Type 2 Diabetes MellitusThe American Journal of Cardiology, 2008
- Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate TreatmentClinical Chemistry, 2008
- Is There a Role for Fibrates in the Management of Dyslipidemia in the Metabolic Syndrome?Arteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993
- Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemiaAtherosclerosis, 1985
- Fenofibrate reduces low density lipoprotein catabolism in hypertriglyceridemic subjects.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1985
- Apolipoprotein A and B (Sf 100-400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects.JCI Insight, 1984
- Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinaemic subjectsAtherosclerosis, 1982